NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Areteia Therapeutics

Areteia Therapeutics

Private
Chapel Hill, North CarolinaHealthcare & Life Scienceshttps://areteiatx.com

Last Round

Series A

Extension

Feb 13, 2024

Total Funding Raised

$425M

Company Overview

Areteia Therapeutics is a biotechnology company that develops oral medications for the treatment of eosinophilic asthma and related inflammatory airway diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydexpramipexoleeosinophilic asthmaoral therapyclinical-stage biotechsmall-molecule drugbiologic alternativeclinical trialsdrug developmentasthma treatmenteosinophil-lowering therapybiotech startuppharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Areteia Therapeutics Comparables

Compare Areteia Therapeutics with similar companies based on industry and business-model similarity.

Areteia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Knopp Biosciences
91%
RAPT Therapeutics
69%
Roche Holding
68%

Areteia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 13, 2024
Series AJul 12, 2022

Key People

Founding team and executive leadership

Christopher Courts

Chief Financial Officer

Executive Team

Areteia Therapeutics Investors

Notable investors and investment history

Areteia Therapeutics investors
InvestorRounds
Maverick CapitalSeries A, Series A Extension
Access IndustriesSeries A, Series A Extension
Bain Capital Life SciencesSeries A, Series A Extension
GVSeries A, Series A Extension
Maverick CapitalSeries A, Series A Extension
ARCH Venture PartnersSeries A, Series A Extension
Viking Global InvestorsSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 26, 2025

    Ian F. Smith appointed Chair of the Audit Committee.

  • Mar 26, 2025

    Donald J. Hayden, Jr. appointed as Chair of the Board.

Areteia Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Areteia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Areteia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersChapel Hill, North Carolina
Employee Range10
Year Founded2022
Last FundingFeb 13, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.